Immunogenic cell death unlocks the potential for combined radiation and immunotherapy
Proceedings of the National Academy of Sciences · 02.12.2025 · 122 (48)
DOI: 10.1073/pnas.2509875122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 26.11.2025. Verfasst von Somiya Rauf und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics and Statistics, Georgia State University, Atlanta, GA 30303. Hauptthemen laut MEDLINE: Immunotherapy, Immunogenic Cell Death, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation (NSF), NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Immunogenic cell death (ICD) enhances antitumor immunity by releasing tumor-associated antigens and activating the antitumor immune system response. Here, we develop a mathematical model to quantify the role of ICD in optimizing the efficacy of combined radiotherapy (RT) and macrophage-based immunotherapy. Using preclinical murine data targeting the SIRP α -CD47 checkpoint, we show that RT alone induces minimal ICD, whereas disrupting the SIRP α -CD47 axis significantly enhances both phagocytosis and systemic immune activation. Our model predicts an optimal RT dose (6 to 8 Gy) for maximizing ICD, a dose-dependent abscopal effect, and a hierarchy of treatment efficacy, with SIRP α -knockout macrophages exhibiting the strongest tumoricidal activity. These findings provide a quantitative framework for designing more effective combination therapies, leveraging ICD to enhance immune checkpoint inhibition and radiotherapy synergy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Mathematics and Statistics, Georgia State University, Atlanta, GA 30303.
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322.
- Key State Laboratory of Pharmaceutical Biotechnology, Nanjing University School of Life Sciences, Nanjing, Jiangsu 210046, China.
ORCID-Profile: Somiya Rauf, Andres Chang, Yi Jiang
Förderung
- National Science Foundation (NSF)
- NIAID NIH HHS
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
- NCATS NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Rauf, S., Smirnova, A., Chang, A., Liu, Y., & Jiang, Y. (2025). Immunogenic cell death unlocks the potential for combined radiation and immunotherapy. Proceedings of the National Academy of Sciences, 122(48). https://doi.org/10.1073/pnas.2509875122
Vancouver
Rauf S, Smirnova A, Chang A, Liu Y, Jiang Y. Immunogenic cell death unlocks the potential for combined radiation and immunotherapy. Proceedings of the National Academy of Sciences. 2025;122(48). doi:10.1073/pnas.2509875122
BibTeX
@article{Rauf2025,
author = {Rauf, Somiya and Smirnova, Alexandra and Chang, Andres and Liu, Yuan and Jiang, Yi},
title = {Immunogenic cell death unlocks the potential for combined radiation and immunotherapy},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {48},
doi = {10.1073/pnas.2509875122}
}
EUVIMED